Verdict: Side-by-side breakdown using the Bull Rankings model. BIIB scored 37.7, KNSA scored 67.1 — KNSA leads.
Compare another set
BIIB
Biogen Inc.
Drug Manufacturers - General · Quality-Growth
37.7
$225.71 · $33.3B
fundamentals as of
Score gap
29.4
KNSA leads
KNSA
Kiniksa Pharmaceuticals International, plc
Drug Manufacturers - Specialty & Generic · Quality-Growth
67.1
$79.78 · $6.2B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
CheapestBIIB40.1x
Fastest growthKNSA+56.7%
Strongest balance sheetKNSA0.01
Highest qualityKNSA64 / 100
Largest discount to fair valueBIIB-2%
Side by side · every name on one set of axes
Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
The model, pillar by pillar (0–100 each)
BIIB
stronger →← stronger
KNSA
58
Qualityreturns · margins · balance sheet
64
32
Growthrevenue & earnings expansion
99
29
Valuevaluation vs sector peers
48
KNSA is stronger on 3 of 3 pillars.
Fundamentals, head-to-head
BIIB
KNSA
$2.4bB
FCF
$164mC
+1.2%C
Rev
+56.7%A
0.44B
D/E
0.01A-
40.1xC
P/E
79.8xD
2.25C
PEG
2.03C
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
BIIB
KNSA
2% below
Price vs fair valuelower is cheaper
63% above
~2%/yr
Growth the price impliesyr-1 FCF growth, fading to 4% · lower = less priced in
~28%/yr
+5%
1-yr DCF upside
-53%
+2%
5-yr DCF upside
-39%
-3%
10-yr DCF upside
-10%
These two disagree on this pair: the Value pillar ranks cheapness against sector peers, while price-vs-fair-value is an absolute read. A name can be the better value in its sector and still the dearer one on cash flows.
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
BIIB
No notable signals flagged.
KNSA
Why this score
Diluting shareholders
The companies
BIIBBiogen Inc.
Drug Manufacturers - General · $225.71 · beta 0.09
Why now
Drug Manufacturers - General · market cap $33.3b. Trading near 52-week high of $230.49 — momentum setup, limited technical margin of safety. 31 sell-side analysts rate this a Buy with a mean 1-yr target of $239.02 (implying +6% upside).
Moat
Net margin 14% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. FCF converts 177% of net income — earnings translate cleanly into cash. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trading within 2% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Trailing P/E 40x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. ROE 7% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.
Drug Manufacturers - Specialty & Generic · market cap $6.2b. 4% off the 52-week high of $82.94. Revenue growing +57% — in hypergrowth territory. 8 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $98.00 (implying +23% upside).
Moat
ROE 12% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. Free cash flow runs well ahead of reported net income. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trailing P/E 79.8x prices in sustained high growth — any quarter that disappoints triggers sharp re-rating. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where BIIB and KNSA diverge
On the headline score the gap is 29.4 points in favor of KNSA. The widest single difference is Growth, where KNSA leads by 67.1 points.
GrowthBIIB 31.9 · KNSA 99.0KNSA +67.1
ValueBIIB 29.1 · KNSA 47.8KNSA +18.7
QualityBIIB 57.7 · KNSA 64.0KNSA +6.3
Pillars run 0–100. Value is judged against each company's own sector, so a Value score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.
Common questions
Is KNSA or BIIB the better stock?
KNSA scores higher: KNSA 67.1, BIIB 37.7 out of 100 on the Bull Rankings quality-growth score, which blends business quality, growth and valuation into one number. A higher score means a stronger business at a more reasonable price — it is not a price target or a recommendation.
Where do KNSA and BIIB differ most?
The widest gap is growth, where KNSA leads by 67 points on the 0–100 pillar scale. KNSA leads all three pillars, so the gap is broad rather than a single-measure difference.
How are KNSA and BIIB scored?
Each carries the same 0–100 quality-growth score used everywhere on the site, built from three pillars — quality (profitability and returns on capital), growth (revenue and earnings), and value (what you pay for them) — combined as a geometric mean, so a weak pillar cannot be papered over by a strong one.
How current is this comparison?
The whole universe is re-scored every trading day after the US market close, so the scores and fundamentals here reflect the latest published edition.